Dipeptidyl‐peptidase IV inhibitor‐associated bullous pemphigoid efficiently treated with omalizumab.

Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab Serum IgG against BP180 titers dropped during omalizumab treatment, but remained elevated (from above 200 UI/mL before treatment to 89 UI/mL after 6 months and to 46 UI/mL after 12 months). Since Fairley et al described the first case of a BP patient efficiently treated with omalizumab, an increasing number of cases of successful treatment has been reported.4 Criteria to select the ideal candidate to anti-IgE-directed therapy remain uncertain. [Extracted from the article]